ChromaGenix helps biopharma innovators overcome some of the most persistent challenges in drug development: how to purify complex biologics such as AAVs, mRNA, and viral vectors, more efficiently, consistently, and at scale.

We specialize in developing synthetic affinity ligands and chromatography resins that are engineered for the production of advanced therapies. Whether you’re working on gene therapy, vaccines, or emerging modalities, ChromaGenix is committed to solving your critical downstream challenges, backed by a culture of innovation, integrity, and scientific rigor.